Earnings Call · Q4 FY2022·2023-02-21

Q4 22EPS -100.00%*·Rev n/aQ3 22EPS +11.54%·Rev n/aQ2 22EPS +8.57%·Rev n/aQ1 22EPS 0.00%·Rev n/a⚠ consensus missing

BIOCRYST PHARMACEUTICALS INC BCRX

John Bluth — Investor Relations or Corporate Communications

Jon Stonehouse — Chief Executive Officer

Charlie Gayer — Head of Commercial or Commercial Leader

Helen Thackray — Chief Scientific Officer

Anthony Doyle — Chief Financial Officer

−15.3%1d on move date−13.3% vs SPY3d−7.5%5d−11.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BCRX calls or request research access.

More BCRX calls Browse calls Request research access